Patients with severe absorption issues and deficiencies often have to inject more often
Neurologically, ALD/AMN can manifest with highly variable phenotypes, ranging from very aggressive and rapidly fatal inflammatory CNS demyelination in young boys to a more slowly progressive adult form either with cerebral white matter inflammatory lesions, or a more indolent progressive myelopathy and peripheral neuropathy (Moser, 1997)
2010;16(3):BR81 to 88
The WHO estimates it affects between 1020% of people infected with SARS-CoV-2 tens of millions globally.1 The symptoms are wide-ranging but cluster into recognizable patterns: Neurological: brain fog, cognitive impairment, headaches, sleep disruption Cardiovascular: chest pain, breathlessness, tachycardia (POTS), reduced exercise tolerance Immune: persistent low-grade inflammation, recurrent infections, autoimmune flares Musculoskeletal: post-exertional malaise (PEM), joint pain, muscle weakness Metabolic/endocrine: insulin dysregulation, thyroid disruption, adrenal fatigue signals Standard care rest, symptom management, antidepressants, rehabilitation programs helps some patients
The Pharmacy Compounding Advisory Committee (PCAC) are discussing and voting on July 23 and 24, then will pass their recommendations to the FDA to make the final call
Journal of Applied Physiology (Bethesda, Md.: 1985) , 110 (3), 774780
